Overall survival (OS) for patients with metastatic colorectal cancer (mCRC) has markedly improved within the last 2 decades and the most recent generation of randomized clinical trials have yielded median OS durations of 30 months or longer.[1–3] Reasons for this improvement are numerous and multifactorial, although three main points are considered to be the most relevant:
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pMnoWo
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Purpose: The MHC-unrestricted activity of cytokine-induced killer (CIK) cells against chemo-surviving melanoma cancer stem cells (mCSC) was...
-
Publication date: 18 April 2017 Source: Cell Reports, Volume 19, Issue 3 Author(s): David Estoppey, Chia Min Lee, Marco Janoschke, Boon He...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oLOayI via IFTTT
-
Cytokine-dependent renewal of stem cells is a fundamental requisite for tissue homeostasis and regeneration. Spermatogonial progenitor cells...
-
Induced overexpression of CD44 associated with resistance to apoptosis on DNA damage response in human head and neck squamous cell carc...
-
Abstract This paper addresses the hybrid consensus-based formation keeping problem for nonholonomic mobile robots in the presence of a nov...
-
Downregulation of mouse CCR3 by lentiviral shRNA inhibits proliferation and induces apoptosis of mouse eosinophils. Mol Med Rep. 2016 ...
-
Vol.20 No.1 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2seUCMY via IFTTT
-
Current treatments for generalized pustular psoriasis are unsatisfactory. We applied recently-developed techniques for transcriptomic analys...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου